Vaccine 2020 Jan 28
Finding equipoise: CEPI revises its equitable access policy.
Huneycutt B, Lurie N, Rotenberg S, Wilder R, Hatchett R
Launched at Davos in January 2017 with funding from sovereign investors and philanthropic institutions, the Coalition for Epidemic Preparedness Innova ...
Read More
Source: PubMed
Health Secur
Improving Cross-Border Preparedness and Response: Lessons Learned from 3 Lassa Fever Outbreaks Across Benin, Nigeria, and Togo, 2017-2019.
Kakai CG, Okunromade OF, Dan-Nwafor CC, Chabi AIB, Martial GTP, Dalhat MM, Ward S, Tante O, Nguku PM, Hamadi A, Ilori E, Lokossou V, Brito C, Ojo OE, Kone I, Agbeko TT, Ihekweazu C, Merrill RD
Long-standing cultural, economic, and political relationships among Benin, Nigeria, and Togo contribute to the complexity of their cross-border connec ...
Read More
Source: PubMed
Antiviral Res. 2020 Jan 22
The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.
Zivcec M, Spiropoulou CF, Spengler JR
For more than 20 years, researchers have used laboratory mice lacking type I or both type I and II interferon (IFN) responses to study high-containmen ...
Read More
Source: PubMed
Travel Med Infect Dis 2020 Jan 21
Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE).
Duvignaud A, Jaspard M, Etafo IC, Serra B, Abejegah C, Gabillard D, Doutchi M, Alabi JF, Adedokun MA, Akinpelu AO, Oyegunle OO, Etafo J, Dede AO, Onyechi MN, Ireneh MU, Gbenga-Ayeni O, Fadiminiyi KG, Ehigbor PI, Ouattara E, Levy-Marchal C, Karcher S, N'guessan-Koffi L, Ahyi I, Amani E, Diabaté M, Siloué B, Schaeffer J, Augier A, Ogbaini-Emovon E, Salam AP, Horby P, Ahmed LA, Günther S, Adedosu AN, Anglaret X, Ayodeji OO, Malvy D
Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority disease by the World Health Organization (WHO) ...
Read More
Source: PubMed
Vaccine 2020 Jan 14
Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10-11 September 2019.
Salami K, Gsell PS, Olayinka A, Maiga D, Formenty P, Smith PG, Moorthy V
At the time of writing in 2019, there have been 754 confirmed cases of Lassa fever in Nigeria, 21% of whom have died. Lassa is on the priority pathoge ...
Read More
Source: PubMed
Vaccine 2020 Jan 28
Finding equipoise: CEPI revises its equitable access policy.
Huneycutt B, Lurie N, Rotenberg S, Wilder R, Hatchett R
Launched at Davos in January 2017 with funding from sovereign investors and philanthropic institutions, the Coalition for Epidemic Preparedness Innova ...
Read More
Source: PubMed
Health Secur
Improving Cross-Border Preparedness and Response: Lessons Learned from 3 Lassa Fever Outbreaks Across Benin, Nigeria, and Togo, 2017-2019.
Kakai CG, Okunromade OF, Dan-Nwafor CC, Chabi AIB, Martial GTP, Dalhat MM, Ward S, Tante O, Nguku PM, Hamadi A, Ilori E, Lokossou V, Brito C, Ojo OE, Kone I, Agbeko TT, Ihekweazu C, Merrill RD
Long-standing cultural, economic, and political relationships among Benin, Nigeria, and Togo contribute to the complexity of their cross-border connec ...
Read More
Source: PubMed
Antiviral Res. 2020 Jan 22
The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.
Zivcec M, Spiropoulou CF, Spengler JR
For more than 20 years, researchers have used laboratory mice lacking type I or both type I and II interferon (IFN) responses to study high-containmen ...
Read More
Source: PubMed
Travel Med Infect Dis 2020 Jan 21
Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE).
Duvignaud A, Jaspard M, Etafo IC, Serra B, Abejegah C, Gabillard D, Doutchi M, Alabi JF, Adedokun MA, Akinpelu AO, Oyegunle OO, Etafo J, Dede AO, Onyechi MN, Ireneh MU, Gbenga-Ayeni O, Fadiminiyi KG, Ehigbor PI, Ouattara E, Levy-Marchal C, Karcher S, N'guessan-Koffi L, Ahyi I, Amani E, Diabaté M, Siloué B, Schaeffer J, Augier A, Ogbaini-Emovon E, Salam AP, Horby P, Ahmed LA, Günther S, Adedosu AN, Anglaret X, Ayodeji OO, Malvy D
Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority disease by the World Health Organization (WHO) ...
Read More
Source: PubMed
Vaccine 2020 Jan 14
Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10-11 September 2019.
Salami K, Gsell PS, Olayinka A, Maiga D, Formenty P, Smith PG, Moorthy V
At the time of writing in 2019, there have been 754 confirmed cases of Lassa fever in Nigeria, 21% of whom have died. Lassa is on the priority pathoge ...
Read More
Source: PubMed
